Evercore ISI Group Maintains Outperform on ProQR Therapeutics, Raises Price Target to $6
Evercore ISI Group analyst Gavin Clark-Gartner maintains ProQR Therapeutics (NASDAQ: PRQR ) with a Outperform and raises the price target from $5 to $6.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.